Chk1/PARP-1 inhibitors (Sentinel Oncology)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameChk1/PARP-1 inhibitors (Sentinel Oncology)
Drug Alias Nametargeted synergy program (Sentinel Oncology)targeted synergy program (Sentinel)S-070S-158
ClassificationSmall molecules
Mechanisms of ActionDNA repair inhibitorsPoly (ADP-Ribose) polymerase 1 inhibitorsCheckpoint kinase 1 inhibitors +[4] 
TargetsPoly (ADP-Ribose) polymerase 1Checkpoint kinase 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSentinel Oncology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSentinel Oncology Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A